Norway· NO-ID_15C10A5F-AD54-48A8-AFAB-3A2C52B3B95D
Increlex
A mecasermin product containing mecasermin, registered in Norway by Esteve Pharmaceuticals S.A. The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Mecasermin is registered in 12 of 19 countries.
Countries holding a registration under ATC H01AC03 (mecasermin), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Mecasermin · ATC H01AC03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Mecasermin
- Manufacturer
- Esteve Pharmaceuticals S.A
- Country
- Norway (NO)
- ATC code
- H01AC03
- ATC class
- Mecasermin
- Defined daily dose
- 2 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_15C10A5F-AD54-48A8-AFAB-3A2C52B3B95D
- no_varenummer4818074NOK 7708.1
- gtin3582186006238
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
25 interactions on record for mecasermin.
Graded by severity as the source publishes them — 25 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mecasermin · interactions on record
25 records
- 25 moderate
Most severe, free to view
- Insulin (human)A10AB01moderate
- Insulin lisproA10AB04moderate
- Insulin aspartA10AB05moderate
- Insulin glulisineA10AB06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Mecasermin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumIncrelex 10 mg/mlEsteve Pharmaceuticals
- CzechiaINCRELEXEsteve Pharmaceuticals S.A., Barcelona
- SpainINCRELEX 10 mg/ml SOLUCION INYECTABLEEsteve Pharmaceuticals S.A.
- IcelandIncrelexEsteve Pharmaceuticals S.A.
- PolandIncrelexIpsen Pharma
- SwedenINCRELEX 10 mg/ml Injektionsvätska, lösningEsteve Pharmaceuticals S.A.
- United StatesGUNA-IGFGuna spa
- CanadaINCRELEXIPSEN BIOPHARMACEUTICALS CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Increlex
- Liechtenstein · Increlex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ede90dc7-0da7-4d55-81d8-9ce4ba3e5d83 GET /v1/drugs/ede90dc7-0da7-4d55-81d8-9ce4ba3e5d83?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Mekasermin",
"merkevare_id": "ID_15C10A5F-AD54-48A8-AFAB-3A2C52B3B95D",
"name_form_strength": "Increlex inj, oppl 10 mg/ml",
"prescription_group": "C"
}See everything about mecasermin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.